BioSpace News Archive

Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2020, after the U.S. markets close on May 6, 2020.

Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, provided an update on its efforts to support customers, communities, and its employees during the COVID-19 pandemic.

DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2020.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported immunogenicity and safety data from an interim analysis of the ongoing clinical trial evaluating HEPLISAV-B® [Hepatitis B Vaccine, Adjuvanted] in patients undergoing hemodialysis.

Cerner Corporation announced results for the 2020 first quarter that ended March 31, 2020.

Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, will release its 2020 first quarter operating results on Tuesday, May 12, 2020, after market close.

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Thursday, May 7, 2020, to discuss the Company’s First Quarter 2020 financial results.

Masimo (Nasdaq: MASI) today announced its financial results for the first quarter ended March 28, 2020.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the closing of its initial public offering of 8,625,000 shares of its common stock,

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.